Ahmed Enayetallah,
Associate Medical Director for Alzheimer’s Disease
Dr. Enayetallah is an Associate Medical Director for Alzheimer’s Disease at Biogen Inc. Dr. Enayetallah obtained his medical degree from School of Medicine at University of Cairo in 1995 and his Ph.D. degree in Pharmacology & Toxicology from School of Pharmacy at University of Connecticut in 2006. Dr. Enayetallah joined Biogen Idec in 2013, where his focus is to identify and implement innovative approaches to investigate clinical, radiographic and molecular variables associated with neurodegenerative disease heterogeneity and progression trajectories. The emphasis is to identify strategies that can leverage optimal treatment selection. Prior to Biogen Idec, Dr. Enayetallah worked at Pfizer Inc. where he served as the drug safety disease area lead for the Biotherapeutics Oncology Research Unit. At Pfizer, Dr. Enayetallah was also a member of the Precision Medicine initiative leading patient stratification and response prediction studies in oncology and autoimmune diseases. Prior to Pfizer Dr. Enayetallah was the personalized medicine lead scientist at Genstruct Inc. (now Selventa Inc.), where he led the application of causal reasoning approaches to profile cancer patients for therapy prioritization. Dr. Enayetallah has over 50 research articles, abstracts, invited talks and oral presentations.
|
|
|
